Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04522089
Recruitment Status : Recruiting
First Posted : August 21, 2020
Last Update Posted : September 24, 2020
Sponsor:
Information provided by (Responsible Party):
Adimmune Corporation

Brief Summary:
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: AdimrSC-2f Phase 1

Detailed Description:

The objectives of this phase I study are:

  1. to evaluate the safety profile of the AdimrSC-2f vaccine, and
  2. to assess the immunogenicity of the AdimrSC-2f vaccine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers
Actual Study Start Date : August 24, 2020
Estimated Primary Completion Date : November 20, 2020
Estimated Study Completion Date : March 20, 2021

Arm Intervention/treatment
Experimental: AdimrSC-2f Group 1
low dose mcg
Biological: AdimrSC-2f
AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Experimental: AdimrSC-2f Group 2
low dose mcg+AL
Biological: AdimrSC-2f
AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Experimental: AdimrSC-2f Group 3
medium dose mcg
Biological: AdimrSC-2f
AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Experimental: AdimrSC-2f Group 4
high dose mcg
Biological: AdimrSC-2f
AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.




Primary Outcome Measures :
  1. The solicited adverse events (SoAEs) [ Time Frame: The 7 days following each vaccination ]
    Determining the solicited adverse events (SoAEs) (the percentage, severity, and relationship to the AdimrSC-2f vaccine) during 7 days following each vaccination.

  2. Incidence of abnormal laboratory tests results [ Time Frame: Day 7 after vaccination ]
    Determining the clinically significant changes in hematology, biochemistry, and coagulation results from baseline at Visit 2 and Visit 4.


Secondary Outcome Measures :
  1. Safety of AdimrSC-2f vaccine: AE [ Time Frame: Day 0 to Day 182 ]
    1. Determining the SoAEs and unsolicited AES (the percentage, severity, and relationship to AdimrSC-2f vaccine) during the study period.
    2. Overall AEs and serious adverse events (SAEs) during the study period.

  2. Immunogenicity [ Time Frame: Day 7,21,28,and 42 ]
    Determining the changes of antibody titers between baseline and the subsequent scheduled visits

  3. Immunogenicity [ Time Frame: Day 21 and 42 ]
    Determining the geometric mean increase (GMI)

  4. Immunogenicity [ Time Frame: Day 21 and 42 ]
    Determining the seroconversion rate (SCR)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who meet ALL inclusion criteria will be included.

    1. Male or non-pregnant female, aged 20 to 60 years old (inclusive).
    2. Subject who is physically and mentally capable of participating the study and are willing to adhere to study procedures.
    3. Subject with no clinically significant abnormal findings in medical history, physical examination, vital signs, or clinical laboratory results at the Screening visit based on the investigator's judgment.
    4. Subject with negative test result in SARS-CoV-2 antibody (IgG and IgM) rapid test at the Screening visit.
    5. Subject with negative serology test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, and hepatitis C antibody at the Screening visit.
    6. Subjects' clinical laboratory test results are in the normal range or with abnormal values without clinical significance as judged by the investigator.
    7. Female subject with childbearing potential must have negative result in urine pregnancy test at the Screening visit.
    8. Female subject with childbearing potential must be willing to implement adequate, highly effective contraceptive measure during the study period. Effective birth control includes:

      1. Intrauterine device plus one barrier method
      2. Oral, implantable, or injectable contraceptives plus one barrier method; or
      3. Two barrier methods Effective barrier methods are male or female condoms, diaphragms, or spermicides (creams or gels that contain a chemical to kill sperm). Women of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year.
    9. Male subject who agrees to use an adequate method of contraception during the study period [e.g., barrier contraceptives (male condom)].
    10. Subject who provides informed consent after receiving a detailed explanation of study procedures.

Exclusion Criteria:

  • Subjects who meet ANY exclusion criteria will be excluded.

    1. Subject with a body mass index (BMI) < 18.5 kg/m2 (underweight) or ≥ 35 kg/m2 (greater than Class I obesity) at the Screening Visit.
    2. Subject with history of cancer (except localized skin cancer without metastases) within 5 years prior to the Screening visit.
    3. Subject has ongoing or medical history of hypertension or diabetes mellitus.
    4. Subject has ongoing use of tobacco or nicotine-containing products (nicotine patch included) or e-cigarette devices or with history of using nicotine-containing product as documented in medical chart or by verbal confirmation at screening.
    5. Subject with documented history of substance or alcohol abuse in the medical chart or by verbal confirmation within 6 months (approximately 180 days) prior to the Screening visit.
    6. Subject who received any vaccine (live, inactivated, or bacterial) within 1 month (approximately 30 days) prior to the Screening visit.
    7. Subject with hypersensitivity to the ingredients of AdimrSC-2f (including aluminum).
    8. Subject with personal or family history of Guillain-Barré Syndrome.
    9. Subject who has travelled abroad within 3 months (approximately 90 days) prior to the Screening visit.
    10. Subject with influenza-like illness as defined by any of the following symptoms at Screening visit: fever (tympanic temperature ≥ 38℃), dry cough, headache, fatigue, respiratory sputum production (phlegm), dysgeusia, anosmia, shortness of breath, muscle and joint pain, or sore throat.
    11. Female subject who is pregnant or lactating at screening or plans to be pregnant during the study period.
    12. Subject who treated with an investigational drug or device or have participated in a clinical study within 3 months (approximately 90 days) prior to the Screening visit.
    13. Subject with clinically significant abnormal ECG at the Screening visit or with history of clinically significant cardiovascular disease such as arrhythmia, coronary artery disease or heart failure, as judged by the investigator.
    14. Subject with any confirmed or suspected abnormal immune function, immunosuppressive, or immunodeficiency or received any immunosuppressants or immunomodulators within 6 months (approximately 180 days) prior to the Screening visit.
    15. Subject with history of wheezing, asthma, chronic obstructive pulmonary disease, or have used bronchodilator within 3 months (approximately 90 days) prior to the Screening visit.
    16. Subject who had blood donation within 2 weeks prior to the Screening visit.
    17. Subject who received any blood products, including immunoglobulin within 3 months (approximately 90 days) prior to the Screening visit.
    18. Subject who is not suitable to participate in this study as judged by the investigator.
    19. Subject with chronic illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04522089


Contacts
Layout table for location contacts
Contact: Ellie Chen +886425381220 ext 1224 ellie_chen@adimmune.com.tw

Locations
Layout table for location information
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Principal Investigator: Shan-Chwen Chang         
Sub-Investigator: Szu-Min Hsieh         
Sub-Investigator: Sung-Ching Pan         
Sub-Investigator: Wang-Da Liu         
Sponsors and Collaborators
Adimmune Corporation
Layout table for additonal information
Responsible Party: Adimmune Corporation
ClinicalTrials.gov Identifier: NCT04522089    
Other Study ID Numbers: ADPCT20011X
First Posted: August 21, 2020    Key Record Dates
Last Update Posted: September 24, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No